Shire Targets More Rare Diseases with Santaris’ LNA Platform
By Taskin Ahmed
Pharma Deals Review: Vol 2009 Issue 9 (Table of Contents)
Published: 8 Sep-2009
DOI: 10.3833/pdr.v2009.i9.1240 ISSN: 1756-7874
Section: Technology Access
Fulltext:
Abstract
Shire’s existing expertise in the treatment of rare genetic disorders has resulted in research and development deal with Santaris Pharma AS of Denmark based on the latter’s proprietary locked nucleic acid (LNA) technology and initiation of the ‘antisense’ approach to RNA-based therapeutics...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS